Similar articles

• 5-HT3 receptor antagonists, a new approach in emesis: a review of ondansetron, granisetron and tropisetron.

  Seynaeve C, Verweij J, de Mulder PH. Seynaeve C, et al. Anticancer Drugs. 1991 Aug;2(4):343-55. doi: 10.1097/00001813-199108000-00003. Anticancer Drugs. 1991. PMID: 1665723 Review.
• Granisetron (BRL 43694) in the treatment of cytostatic drug-induced emesis: a summary.

  Pintens H. Pintens H. Cancer Treat Rev. 1990 Sep;17(2-3):307-10. doi: 10.1016/0305-7372(90)90062-k. Cancer Treat Rev. 1990. PMID: 2176932 Review. No abstract available.
• Antiemetic control: 5-HT3 antagonists: review of clinical results, with particular emphasis on ondansetron.

  Kidgell AE, Butcher ME, Brown GW. Kidgell AE, et al. Cancer Treat Rev. 1990 Sep;17(2-3):311-7. doi: 10.1016/0305-7372(90)90063-l. Cancer Treat Rev. 1990. PMID: 2176933 Review. No abstract available.
• Review of experience with ondansetron and granisetron.

  Aapro MS. Aapro MS. Ann Oncol. 1993;4 Suppl 3:9-14. doi: 10.1093/annonc/4.suppl_3.s9. Ann Oncol. 1993. PMID: 8395875 Review.
• 5-HT3-receptor antagonists in the control of delayed-onset emesis.

  Gridelli C. Gridelli C. Anticancer Res. 2003 May-Jun;23(3C):2773-82. Anticancer Res. 2003. PMID: 12926112 Review.